Tissue Penetration of Antibiotics in Obesity
Information source: Washington University School of Medicine
Information obtained from ClinicalTrials.gov on February 12, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Obesity
Phase: N/A
Status: Recruiting
Sponsored by: Washington University School of Medicine Official(s) and/or principal investigator(s):
Evan D Kharasch, MD, PhD, Principal Investigator, Affiliation: Washington University School of Medicine
Summary
The purpose of this study is to evaluate cefoxitin pharmacokinetics in obese surgical
patients.
Clinical Details
Official title: Tissue Penetration of Antibiotics in Obesity
Study design: Case Control, Prospective
Primary outcome: plasma and tissue cefoxitin concentrations at the time of incision
Secondary outcome: cefoxitin pharmacokinetic parameters
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- BMI <25 and >40
- Scheduled for elective abdominal or pelvic surgery
- Surgical plan for intraoperative cefoxitin prophylaxis
- Able to provide informed consent
Exclusion Criteria:
- Allergy to Cefoxitin
- Renal or Hepatic insufficiency
Locations and Contacts
Barnes Jewish Hospital, St. Louis, Missouri 63110, United States; Recruiting
Evan D Kharasch, MD, PhD, Phone: 314-362-7551, Email: kharasch@wustl.edu
Patty M Suntrup, BA, CCRP, Phone: 314-747-1709, Email: suntrupp@wust.edu
Evan D Kharasch, MD, PhD, Principal Investigator
Additional Information
Starting date: February 2008
Ending date: July 2009
Last updated: February 12, 2009
|
